Journal of Adolescent Health
Volume 39, Issue 5 , Pages 642-648, November 2006

Adolescent HIV Prevalence, Sexual Risk, and Willingness to Participate in HIV Vaccine Trials

  • Heather B. Jaspan, M.D., Ph.D.

      Affiliations

    • Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
    • Corresponding Author InformationAddress correspondence to: Dr. Heather Jaspan, Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory 7925, Cape Town, South Africa.
  • ,
  • Jessica R. Berwick, B.S.

      Affiliations

    • Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
  • ,
  • Landon Myer, Ph.D.

      Affiliations

    • School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
  • ,
  • Catherine Mathews, Ph.D.

      Affiliations

    • School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
    • Health Systems Research Unit, Medical Research Council, South Africa, Cape Town, South Africa
  • ,
  • Alan J. Flisher, M.B.Ch.B., Ph.D.

      Affiliations

    • Division of Child and Adolescent Psychiatry, University of Cape Town, Cape Town, South Africa
  • ,
  • Robin Wood, M.Med.

      Affiliations

    • Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
  • ,
  • Linda-Gail Bekker, M.B.Ch.B., Ph.D.

      Affiliations

    • Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa

Received 13 February 2006; accepted 19 May 2006. published online 28 July 2006.

Abstract 

Purpose

To determine human immunodeficiency virus (HIV) prevalence, sexual risk behaviors, and attitudes toward HIV vaccine trials among 11–19 year-olds in a peri-urban community near Cape Town, South Africa.

Methods

We performed HIV antibody testing on oral transudate, and assessed sexual risk behaviors and willingness to participate in HIV vaccine trials using self-administered questionnaires.

Results

Of the 510 adolescents selected, 356 (73%) participated. The HIV prevalence of the group was 10.6% (95% confidence interval [CI] 7.5–14.4). One-third of adolescents had experienced sexual debut, with a mean age of 14.6 years. Number of lifetime sexual partners was independently associated with HIV infection (odds ratio [OR] = 1.62; 95% CI 1.1–2.3). In a multivariate analysis, increasing age, female gender, and attending school were independently associated with having had sex. The majority of adolescents (79%) were willing to participate in an HIV vaccine trial. Increasing age and length of residence in the community were significantly associated with willingness to participate (OR = 1.19; 95% CI 1.01–1.4 and OR = 1.14; 95% CI 1.03–1.26, respectively).

Conclusions

The prevalence of HIV and risk behavior among adolescents in this community is high. HIV vaccines are required that target preadolescents. HIV vaccine trials in adolescents in this setting will be facilitated by their willingness to participate.

Keywords: Adolescents, HIV vaccine trials, HIV prevalence, HIV risk, South Africa

 

PII: S1054-139X(06)00196-0

doi:10.1016/j.jadohealth.2006.05.016

Journal of Adolescent Health
Volume 39, Issue 5 , Pages 642-648, November 2006